




THE DRUG DEVELOPMENT ACCELERATOR

myriamed's screening services - myrScreen

myrPlate



myrCell

- Human iPSC-derived
 - > Cardiomyocytes
 - > Skeletal muscle cells
 - > Fibroblasts

myrTissue

Engineered macrophysiological systems

myrScreen

Two-tiered phenotypic screen



PRODUCT INFORMATION

myrCell products derived from well characterized induced pluripotent stem cell (iPS) lines obtained from healthy (**myrHealth** iPSC portfolio) or diseased (**myrDisease** iPSC portfolio) subjects, including CRISPR engineered models.

Differentiation according to defined proprietary protocols in:

- Cardiomyocytes (**myrCell-Cardio** Product Line)
- Skeletal Muscle Cells (**myrCell-Skeletal** Product Line)
- Fibroblasts (**myrCell-Stroma** Product Line)

myrTissue are developed as organoids directly from iPSC lines or engineered from differentiated **myrCell** products to recapitulate organ function in the dish:

- Heart muscle (**myrTissue-Cardio**)
- Skeletal muscle (**myrTissue-Skeletal**)
- Connective tissue (**myrTissue-Stroma**)

Standardization and automation of **myrTissue** production via **myrPlate** platform

Automated analysis of **myrTissue** function via **myrImager** developed in collaboration with **SYNENTEC**

AI-supported deep phenotyping of **myrCell** and **myrTissue** products under Service or Risk Sharing agreements

myrHealth

myrDisease



myrCell



myrTissue



myrPlate



myrImager



myrScreen

KEY BENEFITS AT A GLANCE

- *Phenotypic screens in human macro-scale tissue/organoids*
- *CRISPR-engineered disease models with isogenic controls*
- *Patient-in-a-dish approach*
- *Support by myrTeam with unsurpassed expertise*
- *Best-in-class starting material and organotypic models*

REFERENCES

Heart Muscle: Tiburcy et al. 2017 Circulation, Streckfuss-Bömeke et al. 2017 J Mol Cell Cardiol, Long et al. 2018 Sci Adv, Tiburcy et al. 2020 STAR Protoc, Hanses et al. 2020 Circulation, Fomin et al. 2021 Sci Transl Med, Del Campo et al. 2022 Cardiovasc Res, Seiberts et al. 2024 Cardiovasc Res, Kyriakopoulou et al. 2024 Nat Cardiovasc Res, WO2015/025030, WO2015/040142, WO2017/207431
Skeletal Muscle: Shahriyari et al. 2022 J Cachexia Sarcopenia Muscle, Shahriyari et al. 2023 STAR Protoc, WO2017/207431, WO2021/074126
Connective tissue: Santos et al. 2019 J Mol Cell Cardiol, Kittana et al. 2021 Int J Nanomedicine, Santos et al. 2021 J Vis Exp, Santos et al. 2022 Biomater Adv, WO2017/207431, WO2022/023451

Commercial use - including applications in research&development, disease modeling, and screening - may require license agreements with myriamed and other third parties. myriamed products are not intended for in vivo use. myriamed products are not for resale or distribution to third parties without myriamed's consent. For-profit organizations please contact: commercial@myriamed.com

MYRIAMED® GMBH · WWW.MYRIAMED.COM

Rudolf-Wissell-Str. 28a · 37079 Göttingen · Germany · Phone +49 551 28878-170 · Email contact@myriamed.com